Covid-19 impact: Rosacea Treatment Market Size to surge at 6.8% CAGR is expected to reach $2.6 Billion in 2025

The global rosacea treatment market size is expected to reach USD 2.6 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 6.8% over the forecast period. Several factors such as an advanced formulations and high prevalence of the disease are forecasted to fuel the market growth.

Rosacea affects more than 400 million people worldwide and the global incidence among adults is estimated at 5%. Less than 1.5 million patients seek treatment, making it a highly underdiagnosed condition. This disease has a higher incidence in women than men, with several studies claiming a possible association between rosacea and menopause. In the absence of an absolute cure, treatment options are largely focused on management of the disease.

The market for rosacea treatment is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape. Rosacea is an underdiagnosed condition and is frequently misdiagnosed as acne. Off-label use of therapeutics pose an intensely competitive space for rosacea-specific treatments.

Topical therapies remain the mainstay for treatment. Topical products captured more than 60% market share in 2017. Although topical items are expected to maintain their lead over oral medicines through the forecast period, the market is witnessing a paradigm shift supported by the increasing inclination towards combination products.

Therapeutic options available for rosacea treatment are antibiotics, alpha agonists, retinoids, immunosuppressants, corticosteroids, antihypertensive agents, and others. Antibiotics are prescribed for the first-line treatment, making them the dominant drug class in 2017-a trend expected to continue through 2025.

The rosacea treatment market growth is supported by strong commercial sales from key products such as Rhofade, Mirvaso, Oracea, MetroGel, Noritate, and Finacea. Although increased penetration of generic drugs is a constraining factor, the impending launch of several promising pipeline products indicate an optimistic future for the global market.

To request a sample copy or view summary of this report, click the link below:

Further key findings from the report suggest:

  • The topical drugs segment held over 65% market share in 2017. These drugs are generally prescribed as first-line treatments and are preferred over other options in terms of convenience and results
  • Alpha agonists is anticipated to be the fastest growing drug class, with a CAGR of over 8% during the forecast period
  • Geographically, North America and Europe are the leading regions as the disease tends to affect people with fair/light skin. Asia Pacific is anticipated to witness the fastest growth owing to improved economic and healthcare scenario
  • Key players operating in the rosacea treatment market include Bayer Schering AG; Bausch Health Companies Inc.; Foamix Pharmaceuticals; Nestlé S.A.; and Allergan Plc.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Create a website or blog at

Up ↑

Create your website with
Get started
%d bloggers like this: